ClinicalTrials.gg
Not yet recruitingNCT07847580PRIMEUpdated Sep 29, 2026

Intranasal Dexmedetomidine and Perioperative Myocardial Injury in Patients Having Percutaneous Coronary Interventions

An interventional study of Intranasal dexmedetomidine and Normal Saline in Coronary Heart Disease and Coronary Artery Disease, sponsored by Second Affiliated Hospital, Zhejiang University, School of Medicine. Not yet recruiting at 1 site in China. Open to participants aged 45 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-09-29.

Primary conditionCoronary Artery DiseaseRegistry: Coronary DiseaseReclassifiedWhy we changed it
Registry
Coronary Disease — the first condition term the registry derived for this study.
ClinicalTrials.gg
Coronary Artery Disease
Why
  1. The study's listed conditions name Coronary Artery Disease, a narrower term within Coronary Disease.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Second Affiliated Hospital, Zhejiang University, School of Medicine · Not applicable, Interventional, and Prevention

Updated Sep 29, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
2,500
Allocation
Randomized
Ages
45 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 543 studies in Coronary Artery Disease with a site in China — 176 open to participants now, 210 under way, 6 of them phase 3. Coronary Artery Disease · China.

Planned enrollment
33rd of 324
2,500 · median 307
Started
2026
with 54 others
No phase
210 of 543
71 open now
Primary completion
2029-06
later than 183 of 209 live
Registered
531st of 543
by date

Among the 543 studies in Coronary Artery Disease with a site in China, this one is the 33rd largest by planned enrollment of the 324 interventional ones that give a count, is one of 55 that started in 2026, is one of 210 with no phase, reaches primary completion later than 183 of the 209 other live ones, and was the 531st registered.

Coronary Artery Disease

4,862 studies on the registry are indexed under Coronary Artery Disease; 893 are open to participants now.

Browse Coronary Artery Disease studies →

Open to participants now

176 of the 543 studies in Coronary Artery Disease with a site in China are open now. Recruiting first, the newest first:

171 more — sign in →

All 176 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 589 Coronary Artery Disease studies recruiting now, 403 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 38 take children under 18; 48 take healthy volunteers.

This study: 45 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 543 studies in Coronary Artery Disease with a site in China, or all of them as a file.
02

Study summary

The goal of this clinical trial is to determine the effect of pre-operative dexmedetomidine on periprocedural myocardial injury in patients having percutaneous coronary intervention (PCI). The specific research hypothesis is that intranasal administration of 100 μg dexmedetomidine (DEX) reduces the incidence of periprocedural myocardial injury within 48 hours after PCI, as compared with normal saline.

Participants will be randomly assigned in a 1:1 ratio to two groups: the dexmedetomidine group and the placebo group.

03

Conditions studied

  • Coronary Heart Disease
  • Coronary Artery Disease

Browse trials for

Keywords

  • Intranasal Dexmedetomidine
  • Perioperative Myocardial Injury
  • Percutaneous Coronary Interventions
04

In context

Coronary Artery Disease Reclassified

4,862 studies on the registry are indexed under Coronary Artery Disease; 893 are open to participants now.

This study's planned enrollment of 2,500 is above the median of 124 across 3,009 interventional studies indexed under Coronary Artery Disease.

Browse Coronary Artery Disease studies →

Lead sponsor

Second Affiliated Hospital, Zhejiang University, School of Medicine is the lead sponsor of 100 studies on the registry; 68 are open to participants now.

Compared within Coronary Artery Disease, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Coronary Disease. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
45 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 45-85 years(inclusive);
  • Able to confirm understanding of risks, benefits, and treatment alternatives of receiving intranasal dexmedetomidine, and he/she or his/her legally authorized representative provides written prior to any study-related procedure.
  • Diagnosed with coronary artery disease with objective evidence of ischemia or silent ischemia, meeting the indications for elective PCI.
  • Designated (ASA) physical status II-Ⅲ (ranging from mild systemic disease to severe underlying conditions; patients with marked limitation in ordinary physical activity, yet still capable of light daily activities).

Exclusion criteria

Exclusion Criteria:

  • Allergy or to dexmedetomidine, including severe sinus bradycardia (resting heart rate \< 50 beats/min), sick sinus syndrome, second-degree or higher atrioventricular block without pacemaker implantation;
  • Patients with severe cardiac insufficiency ( \< 40% or functional class Ⅲ-IV), cardiogenic shock, or hemodynamic instability;
  • Uncontrolled hypertension (systolic blood pressure > 180 mmHg or diastolic blood pressure > 110 mmHg) or hypotension (systolic blood pressure \< 90 mmHg);
  • > 30 kg/m²;
  • Known or suspected sleep apnea;
  • Use of drugs that may interfere with the study medication within 1 week before surgery, including α2-adrenergic receptor agonists (e.g., clonidine) or antagonists, and tricyclic antidepressants;
  • Language, visual, or hearing impairment that may affect questionnaire assessment;
  • Hepatic or renal insufficiency (/Aspartate Aminotransferase/Creatinine > 3 times the );
  • Nasal anatomical abnormalities interfering with nasal spray administration;
  • Pregnant or lactating women;
  • Participation in another clinical trial that may conflict with this trial.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

06

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
2,500 participants (estimated)

Study arms

  • Experimental
    Intranasal DEX group

    Patients will receive intranasal DEX (100 μg) 60 ± 10 minutes before the procedure in the preoperative preparation area, with the solution equally sprayed into both nostrils (two sprays per nostril).

    Drug: Intranasal dexmedetomidine

  • Placebo comparator
    Placebo group

    Patients will receive an equal volume of intranasal normal saline containing no active ingredient 60 ± 10 minutes before the procedure.

    Drug: Normal Saline

Interventions

  • Patients will receive intranasal DEX (100 μg) 60 ± 10 minutes before the procedure in the preoperative preparation area, with the solution equally sprayed into both nostrils (two sprays per nostril).

  • DrugNormal Saline

    Patients will receive an equal volume of intranasal normal saline containing no active ingredient.

07

What researchers measure

Primary outcomes

  1. Myocardial injury occurring within 48 hours after surgery

    In patients with a normal baseline cardiac troponin (cTn, whether non-high sensitivity cTnT or cTnI) concentration (≤99th percentile upper reference limit \[URL\]), postoperative cTn elevation exceeding the 99th percentile URL. In patients with an elevated baseline cTn concentration (\>99th percentile URL) that was stable or decreasing, a postoperative cTn increase of \>20% from baseline, with an absolute value exceeding the 99th percentile URL

    Time frame: Within 48 hours after surgery

Secondary outcomes

  1. Delirium within the first postoperative day

    The 3D-CAM scale will be used to evaluate participants for postoperative delirium.

    Time frame: Within the first postoperative day

  2. Acute kidney injury in 48 hours after PCI

    An absolute increase in serum creatinine of ≥0.3 mg/dL within 48 hours after PCI, or a relative increase in serum creatinine of ≥50% within 7 days after PCI

    Time frame: Within 48 hours after PCI.

  3. A collapsed (one or more) composite of serious cardiovascular complications within 30 days after PCI

    Components of the composite are: (1) myocardial infarction; (2) new-onset stroke or transient ischemic attack (TIA); (3) all-cause mortality; (4) any unplanned repeat revascularization; (5) arrhythmias requiring electrical or pharmacological treatment.

    Time frame: Within 30 days after PCI

Other outcomes

  1. Postoperative first-night sleep quality

    Sleep quality during the surgical night will be assessed using the Richards-Campbell Sleep Questionnaire (RCSQ) on the morning of postoperative day 1.This scale consists of 6 dimensions, each scored on a scale of 0 to 100, with higher scores indicating better sleep quality.

    Time frame: Postoperative day 1.

  2. Perioperative anxiety score

    Peri-operative anxiety status will be assessed with the Perioperative Anxiety Scale-7 (PAS-7). This scale consists of 7 dimensions, each scored on a scale of 0 to 4, with higher scores indicating more severe anxiety symptoms.

    Time frame: From study drug administration to 6 hours after PCI.

  3. Peak postoperative cardiac troponin

    Marker values will be standardised (multiples of the upper-reference-limit, ×URL) according to different types of cardiac biomarkers.

    Time frame: Within 48 hours after PCI

  4. Intraoperative pain score

    Pain intensity assessed immediately post-procedure by Numeric Rating Scale(NRS). This scale is scored on a scale of 0 to 10, with higher scores indicating more severe pain.

    Time frame: Immediately post-procedure.

  5. The EuroQol Five-Dimensional Questionnaire (EQ-5D) scores at 30 days after PCI

    Assessed by the EuroQol Five-Dimensional Questionnaire (EQ-5D) at 30 days post-PCI. The EQ-5D comprises 5 dimensions and a visual analogue scale. Each dimension is rated at 5 levels. The EuroQol visual analogue scale (EQ-VAS) requires patients to rate their current overall health on a 0-100 visual analogue scale, where 0 represents the worst health state imaginable and 100 represents the best health state imaginable.

    Time frame: At 30 days post-PCI.

  6. The Kansas City Cardiomyopathy Questionnaire (KCCQ) scores at 30 days after PCI

    The KCCQ comprises 23 items across 7 domains, each scored on a scale of 0 to 100, with higher scores indicating better health status.

    Time frame: At 30 days post-PCI.

  7. Acute adverse reactions

    Acute adverse reactions include allergy, dizziness, nausea, vomiting, and other related manifestations.

    Time frame: Within the period from drug administration to 6 hours after surgery

  8. Hypotension

    A mean arterial pressure (MAP) below 65 mmHg or a reduction of more than 30% from baseline.

    Time frame: Within the period from drug administration to 6 hours after surgery.

  9. Severe bradycardia

    A heart rate below 40 beats per minute.

    Time frame: Within the period from drug administration to 6 hours after surgery.

  10. Hypoxemia

    An oxygen saturation below 90% lasting for at least 30 seconds.

    Time frame: Within the period from drug administration to 6 hours after surgery.

  11. Dosage of vasoactive agents

    Vasoactive agents includes atropine, norepinephrine, and nitroglycerin.

    Time frame: Within the period from drug administration to 6 hours after surgery.

  12. Local nasal adverse reactions

    Local nasal adverse reactions: including nasal discomfort, irritation, nasal congestion, rhinorrhoea, epistaxis, dysgeusia, and incomplete delivery of study nasal-spray medication.

    Time frame: Within the period from drug administration to 6 hours after surgery.

08

Study locations

1 site
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2026; primary completion for Jun 2029, 33 months later.

Of 753 non-industry interventional studies with no phase under Coronary Artery Disease, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 53. This study's planned 33 months is close to that.

Counting every sponsor, half of 930 studies reached it within 30 months; a quarter within 15 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 16, 2026
First posted
Sep 29, 2026
StartEst.
Sep 30, 2026
Primary completionEst.
Jun 30, 2029
CompletionEst.
Jul 31, 2029
Last update
Sep 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Sep 29, 2026
Show all 1 update
  1. Sep 29, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT07847580
Responsible party
Sponsor
First posted
Sep 29, 2026
Start date
Sep 30, 2026 (estimated)
Primary completion
Jun 30, 2029 (estimated)
Completion
Jul 31, 2029 (estimated)
Last update
Sep 29, 2026

Study contacts

Min Yan, Doctor
Contact
zryanmin@zju.edu.cn
15888210247

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dexmedetomidine

Start the discussion